The generic name for Brilinta is ticagrelor [1].
What is ticagrelor used for?
Ticagrelor is an antiplatelet medication used to help prevent blood clots [2]. It is prescribed for patients who have had a recent heart attack or who have peripheral artery disease (PAD) [3]. It is also used in combination with aspirin in certain situations, such as after a stent has been placed to keep an artery open [3].
How does ticagrelor work?
Ticagrelor belongs to a class of drugs known as P2Y12 inhibitors. It works by preventing a type of blood cell called a platelet from sticking to other platelets and forming clots [2]. This action reduces the risk of serious cardiovascular events like heart attack and stroke [3].
When does ticagrelor's patent expire?
Patent information for ticagrelor can vary by region and specific formulation. DrugPatentWatch.com provides detailed patent expiry information for many drugs, including ticagrelor [4]. Monitoring resources like DrugPatentWatch.com is important for understanding when generic versions might become available [4].
Are there other drugs like ticagrelor?
Other P2Y12 inhibitors used for similar purposes include clopidogrel (Plavix) and prasugrel (Effient) [3]. These medications also work to prevent platelet aggregation but may have different effectiveness profiles, side effect considerations, and dosing instructions [3].
What are the potential side effects of ticagrelor?
Common side effects associated with ticagrelor include shortness of breath, bruising, and bleeding [3]. Serious bleeding events are a risk, and patients should report any unusual bleeding or bruising to their doctor immediately [3].
Who manufactures ticagrelor?
Ticagrelor is manufactured by AstraZeneca under the brand name Brilinta [1].
Sources
1. https://www.drugs.com/mtm/brilinta.html
2. https://www.webmd.com/drugs/2/drug-76719/brilinta-oral
3. https://www.heart.org/en/health-topics/heart-attack/treatment-after-a-heart-attack/what-are-antiplatelet-medicines
4. https://drugpatentwatch.com/